v3.24.0.1
Revenue
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The Company provides orthopedic solutions, including products and services spanning the full continuum of patient care, from injury prevention to rehabilitation. While the Company’s sales are primarily derived from three sales channels including dealers and distributors, insurance, and direct to consumers and hospitals, substantially all its revenue is recognized at a point in time. The Company disaggregates its revenue into the following geographic or product groupings:

Year Ended December 31,
202320222021
(In thousands)
Prevention & Recovery:
U.S. Bracing & Support$456,129 $437,287 $432,963 
U.S. Other P&R269,826 255,305 243,051 
International P&R
350,821 335,036 350,015 
Total Prevention & Recovery1,076,776 1,027,628 1,026,029 
Reconstructive:
U.S. Reconstructive426,405 370,173 323,187 
International Reconstructive204,016 165,300 76,972 
Total Reconstructive630,421 535,473 400,159 
Total$1,707,197 $1,563,101 $1,426,188 

Given the nature of the businesses, the Company does not generally have unsatisfied performance obligations with an original contract duration of greater than one year.

The nature of the Company’s contracts gives rise to certain types of variable consideration, including rebates, implicit price
concessions, and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue.

Allowance for Credit Losses

The Company estimates current expected credit losses on trade receivables using historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts. Management disaggregate trade receivables into business segments due to risk characteristics unique to each segment given the individual lines of business and market. Pooling was further disaggregated based on either geography or product type.

The Company leveraged historical write-offs over a defined lookback period in deriving a historical loss rate. The expected credit loss model further considers current conditions and reasonable and supportable forecasts using an adjustment for current and projected macroeconomic factors. Management identified appropriate macroeconomic indicators based on a tangible correlation to historical losses considering the location and risks associated with the Company.

A summary of the activity in the Company’s allowance for credit losses included within Trade receivables in the Consolidated Balance Sheets is as follows:
Year Ended December 31, 2023
Balance at
Beginning
of Period		Charged to Expense, netWrite-Offs, Deductions and Other, netForeign
Currency
Translation		Balance at
End of
Period
(In thousands)
Allowance for credit losses$7,965 $4,836 $(3,221)$151 $9,731